Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use
Addressing Mental Health Comorbidities: Integrated CBT to Improve Functioning in Veterans With Co-Occurring Anxiety and Substance Use
Individual with anxiety and post-traumatic stress disorder often use alcohol in ways that could cause them harm. Treating both mental health concerns and alcohol use at the same time can help reduce difficulties engaging in multiple treatments. The investigators are evaluating how a cognitive behavioral therapy program that helps Veterans with anxiety, posttraumatic stress disorder, and alcohol use at the same time can help improve the participants lives.
Study Overview
Status
Intervention / Treatment
Detailed Description
Co-occurring hazardous drinking, anxiety disorders, and PTSD are problematic combinations of mental health concerns experienced by deployed Veterans. Veterans who have been deployed are at particular risk for experiencing problems in functioning and reintegration related to mental health disorders and hazardous drinking. Co-occurring anxiety and hazardous drinking heavily impact psychosocial functioning and quality of life. Although cognitive behavior therapy (CBT) can promote psychological recovery through improvements in functioning and quality of life, most CBT protocols do not address co-occurring disorders, leading to inefficient and disjointed treatment. The current research seeks to adapt and test the Unified Protocol (UP) for deployed Veterans with hazardous drinking. The use of combined CBT for both anxiety disorders and hazardous drinking has the potential to more efficiently and effectively improve functioning, reduce symptoms, and promote psychosocial recovery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030-4211
- Michael E. DeBakey VA Medical Center, Houston, TX
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- meeting diagnostic criteria for current anxiety disorder
- endorsing hazardous alcohol use
Exclusion Criteria:
-need for acute medically-supervised detoxification with exclusionary criteria of
- high-risk suicidality
- psychotic symptoms, or
- cognitive impairment that could interfere with engagement in weekly psychotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: UP-A
Cognitive behavior therapy (CBT) using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules. |
Transdiagnostic cognitive behavior therapy (CBT) for emotional disorders modified to include CBT for alcohol use. |
|
Active Comparator: Enhanced Usual Care
Referrals to VA care for SUD and anxiety |
Referrals to VA care for SUD and anxiety |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Social Adjustment Scale- Self Report
Time Frame: 2-weeks
|
Evaluates individuals' satisfaction with social situation. Greater scores reflect greater social/occupational impairment (range 42-210). |
2-weeks
|
|
Beck Anxiety Inventory
Time Frame: past 30 days
|
Evaluates levels of anxiety in past month. Higher scores reflect greater anxiety (range 0-63). |
past 30 days
|
|
Addiction Severity Index
Time Frame: 30 days
|
Assessment of substance use and related problems. Higher scores in each domain indicate problems related to substance use in that domain (range for each domain 0-1). |
30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anthony Ecker, PhD, Michael E. DeBakey VA Medical Center, Houston, TX
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D3520-W
- 1IK2RX003520-01A2 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.